Virtual Biobanking for Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARP
- PDF / 216,206 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 31 Downloads / 153 Views
EDITORIAL – SARCOMA
Virtual Biobanking for Retroperitoneal Sarcoma: A Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) Initiative Eisar Al-Sukhni, MD, MSc1, Winan J. van Houdt, MD, PhD2, Sally M. Burtenshaw, MSc1, Yael Babichev, PhD1, Chandrajit P. Raut, MD, MSc3, Marco Fiore, MD4, Elizabeth G. Demicco, MD, PhD5, Alessandro Gronchi, MD4, and Rebecca A. Gladdy, MD, PhD1 1
Surgical Oncology, Princess Margaret Cancer Centre, Mount Sinai Hospital, Department of Surgery, University of Toronto, Toronto, ON, Canada; 2Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; 3Surgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; 4Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 5Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
Sarcomas are rare tumors comprising more than 70 distinct histologic types. The broad spectrum of behavior of these tumors, in addition to the lack of effective standard therapeutic agents for most, are factors underlying the need for translational research in this field. Biobanking—the collection of biomaterials as well as associated clinical, pathologic, and molecular data—facilitates translational research by providing the material not only to investigate the molecular contributors of tumor pathogenesis but also to develop new treatments and investigate their effectiveness on an individual level (i.e., personalized medicine).1 Pooling resources from multiple biobanks can further this goal by providing a larger foundation of specimens on which to build translational research.2 For diseases, such as sarcoma, that consist of numerous rare distinct types, collaboration is critical to achieve sufficient numbers to define molecular mechanisms and to develop prognostic biomarkers.
Electronic supplementary material The online version of this article (https://doi.org/10.1245/s10434-020-08775-1) contains supplementary material, which is available to authorized users. Ó Society of Surgical Oncology 2020 First Received: 18 April 2020 R. A. Gladdy, MD, PhD e-mail: [email protected]
The Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) was established in 2013 with the goal to evaluate the current evidence on retroperitoneal sarcoma and to develop consensus guidelines.3 Current membership encompasses 119 institutions across Europe, North America, Central America, Asia, and Australia. Members are clinicians and scientists with interest in the management of retroperitoneal sarcoma, although the majority also treat sarcomas that arise in other sites. Many are affiliated with high-volume sarcoma centers, which are regional and national centers of excellence. We sought to describe the current state of sarcoma biobanking amongst high-volume sarcoma centers worldwide and to gauge interest in collaboration. Members of TARPSWG were surveyed to defin
Data Loading...
